公开(公告)号：WO2006059169A3

公开(公告)日：2007-02-22

申请号：PCT/HU2005000122

申请日：2005-11-15

Applicant: SINNEX MUESZAKI FEJLESZTOE ES ,  SZILBEREKY JENOE ,  JEDNAKOVITS ANDREA ,  KOLTAI ERNOENE ,  ORBAN GYULA ,  BIRO KATALIN

Inventor： SZILBEREKY JENOE ,  JEDNAKOVITS ANDREA ,  KOLTAI ERNOENE ,  ORBAN GYULA ,  BIRO KATALIN

IPC: A61K31/198 ,  A61K31/23 ,  A61K33/04 ,  A61K33/30 ,  A61P31/12 ,  A61P37/04

CPC classification number: A61K33/04 ,  A61K31/198 ,  A61K31/23 ,  A61K33/30 ,  A61K2300/00

Abstract: The invention relates to a novel antiviral and immune-simulating pharmaceutical composition, containing as active ingredient 20-85 mass% of a ?-3-polyunsaturated fatty acid ester, in fish oil concentrate containing 20-70 mass% of a 5,8,11,14,17-eicosapentaenic acid ester and a 4,7,10,13,16,19-docosahexaenic acid ester, further l-lysine of a salt thereof, optionally a zinc salt, selenium or a selenium compound, as well as additives and carrier ingredients.

Abstract translation: 本发明涉及一种含有20〜85质量％的5-8质量％的含有20-85质量％的α-3-多不饱和脂肪酸酯作为活性成分的新型抗病毒和免疫模拟药物组合物， 11,14,17-二十碳五烯酸酯和4,7,10,13,16,19-二十二碳六烯酸酯，其盐的其它l-赖氨酸，任选的锌盐，硒或硒化合物，以及 添加剂和载体成分。

公开(公告)号：WO1995030649A1

公开(公告)日：1995-11-16

申请号：PCT/HU1995000014

申请日：1995-05-04

Applicant: BIOREX KUTATO ÉS FEJLESZTO"e; RT. ,  BARABAS, Mihály ,  MARVANYOS, Ede ,  ÜRÖGDI, László ,  VERECZKEY, László ,  JASZLITS, László ,  BIRO, Katalin ,  JEDNAKOVITS, Andrea ,  RADVANYI, Erzsébet ,  UDVARDY-NAGY, Istvánné

Inventor： BIOREX KUTATO ÉS FEJLESZTO"e; RT.

IPC: C07C259/02

CPC classification number: C07D295/088 ,  C07C259/02 ,  C07C259/18 ,  C07D213/78

Abstract: The invention relates to novel compounds of formula (I), wherein X means halogen; Z stands for an aromatic group, pyridinyl group or the like; and R represents an alkyl or phenylalkyl group or an -A-N(R1)R2 group, and in the latter R1 and R2 stand, independently from each other, for hydrogen or alkyl group; or R1 and R2, together with the adjacent nitrogen atom, form a 5- to 7-membered, saturated heterocyclic group optionally containing an additional nitrogen, oxygen or sulfur atom, said heterocyclic group optionally being substituted by at least one alkyl group; and A stands for a straight or branched chain alkylene group, as well as the pharmaceutically acceptable acid addition salts thereof; furthermore, to processes for the preparation of the above novel compounds, and pharmaceutical compositions containing these compounds or their pharmaceutically acceptable acid addition salts as active ingredients. Further, the invention relates to certain novel intermediates of formula (II). The compounds of formula (I) possess anti-ischaemic effect and therefore, they are useful for treating ischaemic states and diseases, e.g. myocardial ischaemia (induced e.g. by occlusion of the coronary arteries).

Abstract translation: 本发明涉及新的式（I）化合物，其中X表示卤素; Z表示芳基，吡啶基等; 并且R表示烷基或苯基烷基或-A-N（R 1）R 2基团，并且在后面的R 1和R 2彼此独立地表示氢或烷基; 或R 1和R 2与相邻的氮原子一起形成任选地含有另外的氮，氧或硫原子的5至7元饱和杂环基，所述杂环基任选被至少一个烷基取代; A表示直链或支链亚烷基，以及其药学上可接受的酸加成盐; 此外，涉及制备上述新化合物的方法，以及含有这些化合物或其药学上可接受的酸加成盐作为活性成分的药物组合物。 此外，本发明涉及式（II）的某些新型中间体。 式（I）化合物具有抗缺血作用，因此它们可用于治疗缺血状态和疾病，例如， 心肌缺血（例如通过冠状动脉闭塞诱发）。

公开(公告)号：WO1997000251A1

公开(公告)日：1997-01-03

申请号：PCT/HU1996000033

申请日：1996-06-14

Applicant: BIOREX KUTATO ES FEJLESZTO RT. ,  ÜROGDI, László ,  MARVANYOS, Ede ,  BARABAS, Mihály ,  JASZLITS, László ,  BIRO, Katalin ,  JEDNAKOVITS, Andrea ,  RADVANYNÉ HEGEDÜS, Erzsébet ,  KÜRTHY, Mária ,  UDVARDY NAGY, Istvánné

Inventor： BIOREX KUTATO ES FEJLESZTO RT.

IPC: C07D295/092

CPC classification number: C07D213/75 ,  C07C275/64 ,  C07D295/088

Abstract: The invention relates to novel hydroxylamine derivatives represented by general formula (I), the pharmaceutically acceptable acid addition salts thereof as well as the pharmaceutical compositions containing the same as active ingredient. Another object of the invention is the preparation of the hydroxylamine derivatives and salts thereof. The compounds according to the invention possess anti-ischaemic effect. In the above formula (I) X is O, -NH or a group of the formula -NR'-, wherein R and R', independently from each other, are alkyl, cycloalkyl, phenylalkyl; a phenyl group optionally substituted with halo, haloalkyl, alkyl, alkoxy or nitro; or an N-containing hetero ring; R is H or alkanoyl; R is H or hydroxy optionally acylated with alkanoyl; and R is a group of the formula -N(R )R wherein R and R , independently from each other, may be H, alkyl or a group of the formula -C(O)-NH-R wherein R is as defined above, or R and R , when taken together with the adjacent nitrogen attached thereto, form a 5 to 7-membered hetero ring which may contain one additional hetero atom selected from nitrogen, oxygen and sulfur and which is optionally substituted with alkyl of phenylalkyl.

Abstract translation: 本发明涉及由通式（I）表示的新型羟胺衍生物，其药学上可接受的酸加成盐以及含有与活性成分相同的药物组合物。 本发明的另一个目的是制备羟胺衍生物及其盐。 根据本发明的化合物具有抗缺血作用。 在上式（I）中，X是O，-NH或式-NR'-的基团，其中R和R'彼此独立地是烷基，环烷基，苯基烷基; 任选被卤素，卤代烷基，烷基，烷氧基或硝基取代的苯基; 或含N的杂环; R 1是H或烷酰基; R 2是任选用烷酰基进行酰化的H或羟基; 并且R 3是式-N（R 4）R 5的基团，其中R 4和R 5彼此独立地可以是H，烷基或式 -C（O）-NH-R，其中R如上定义，或R 4和R 5与连接在其上的相邻氮原子一起形成5至7元杂环，其可以含有一个 选自氮，氧和硫的另外的杂原子，其任选被苯基烷基的烷基取代。

公开(公告)号：WO1997016439A1

公开(公告)日：1997-05-09

申请号：PCT/HU1996000064

申请日：1996-11-01

Applicant: BIOREX KUTATO ÉS FEJLESZTO RT. ,  VIGH, László ,  LITERATI NAGY, Péter ,  SZILBEREKY, Jeno"e; ,  ÜRÖGDI, László ,  JEDNAKOVITS, Andrea ,  JASZLITS, László ,  BIRO, Katalin ,  MARVANYOS, Ede ,  BARABAS, Mihály ,  HEGEDÜS, Erzsébet ,  KORANYI, László ,  KÜRTHY, Mária ,  BALOGH, Gábor ,  HORVATH, Ibolya ,  TÖRÖK, Zsolt ,  UDVARDY, Éva ,  DORMAN, György ,  MEDZIHRADSZKY, Dénes ,  MÉZES, Bea ,  KOVACS, Eszter ,  DUDA, Erno"e; ,  FARKAS, Beatrix ,  GLATZ, Attila

Inventor： BIOREX KUTATO ÉS FEJLESZTO RT.

IPC: C07D333/38

CPC classification number: C07D213/78 ,  C07C259/02 ,  C07C259/18 ,  C07C275/64 ,  C07C279/18 ,  C07C2601/14 ,  C07D213/89 ,  C07D215/54 ,  C07D217/26 ,  C07D295/088 ,  C07D307/68 ,  C07D333/38 ,  C07D409/12 ,  C07D413/04

Abstract: A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, a hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which a hydroxylamine derivative is administered is a eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). The invention also provides novel hydroxylamine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.

Abstract translation: 提供了增加细胞分子伴侣表达和/或提高细胞中分子伴侣活性的方法。 所述方法包括用有效量的某种羟胺衍生物处理暴露于生理应激的细胞，所述生理应激诱导细胞表达分子伴侣以增加应激。 或者，可以在细胞暴露于诱导细胞分子伴侣表达的生理应激之前向细胞施用羟胺衍生物。 优选地，施用羟胺衍生物的细胞是真核细胞。 羟胺衍生物对应于式（I）或（II）。 本发明还提供了落入式（I）和（II）范围内的新型羟胺衍生物以及包含所述化合物的药物和/或化妆品组合物。

公开(公告)号：WO1993016107A1

公开(公告)日：1993-08-19

申请号：PCT/US1993001135

申请日：1993-02-09

Applicant: INTERFERON SCIENCES, INC. ,  TESTA, Douglas ,  LIAO, Mei-June ,  FERENCZ-BIRO, Katalin ,  RASHIDBAIGI, Abbas ,  DIPAOLA, Mario ,  PADHYE, Manisha

Inventor： INTERFERON SCIENCES, INC.

IPC: C07K15/26

CPC classification number: C07K14/56 ,  A61K38/00

Abstract: This invention provides a novel improved alpha interferon composition characterized by high specific activity, a purity of greater than 95 % and which upon use in humans is further characterized by a substantial reduction in side effects normally associated with alpha interferon compositions. Also provided is a method for large scale production of the composition from human peripheral blood leukocytes. This alpha interferon composition may be used therapeutically in the treatment of cancers and diseases of the immune system and/or viral etiology.

Abstract translation: 本发明提供了一种新的改进的α干扰素组合物，其特征在于高比活性，纯度大于95％，并且其在人类中的使用进一步的特征在于通常与α干扰素组合物相关的副作用的显着降低。 还提供了用于从人外周血白细胞大规模生产组合物的方法。 该α干扰素组合物可用于治疗癌症和免疫系统疾病和/或病毒病因学。